Halozyme and Oruka sign agreement for Hypercon technology

Halozyme Hypercon has signed an exclusive global collaboration and licence agreement with Oruka Therapeutics to develop ORKA-001 using Hypercon Technology. The collaboration targets the development of ORKA-001 and allows for expansion to one additional target. The Hypercon technology makes drug administration patient-friendly. Credit: Premreuthai / Shutterstock.com. Halozyme Hypercon has signed an exclusive global collaboration and licence agreement with Oruka Therapeutics for the development of ORKA-001 using Hypercon Technology. Oruka has licensed the Halozyme technology for use with its lead programme, ORKA-001, which is in development to treat psoriasis and related inflammatory conditions, and up to one additional target. LOA and…

Source: Pharmaceutical Technology